SNN
Smith & Nephew plc32.31
+0.08+0.25%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Phasing details, China stability affirmed
Q&A delivered granular 2026 phasing, with revenue growth softening to 4.5-5% in H1 before accelerating to 7.5-8% in H2 on Landmark Knee and Allevyn Complete Care ramps, alongside trading profit at 5.5-6% then 9-10%. China sales hold flat at ~$160M YoY, neutralizing topline drag as Sports rebounds offset smaller AET/ENT VBPs, with $15-20M profit hit. Skin subs face 15-20% revenue drop from pricing yet flat volumes via OASIS offsets, maintaining $20-40M guidance impact amid competitor downgrades. REGENETEN hit multiple hundreds of millions. US Knees softens H1 for Ortho360 capital discipline. China won't drag topline anymore. Management addressed concerns directly; watch skin adaptation and Knee ramp.
Key Stats
Market Cap
13.71BP/E (TTM)
29.11Basic EPS (TTM)
1.11Dividend Yield
0.01%IPO
Website
Employees
Sector
Industry
BVS
Bioventus Inc.
7.52+0.02
DYNT
Dynatronics Corp.
0.04+0.00
ENOV
Enovis Corporation
26.07-0.47
IART
Integra LifeSciences Holdings C
13.00-0.47
KIDS
OrthoPediatrics Corp.
17.91-0.08
MDNC
MEDINOTEC INC
5.00+0.00
MDT
Medtronic plc.
97.72-0.85
SNWV
SANUWAVE Health, Inc.
31.46-0.18
SYK
Stryker Corporation
351.69-3.62
ZBH
Zimmer Biomet Holdings, Inc.
90.91-1.52